Sanofi/AstraZeneca Win Beyfortus Approval To Prevent RSV In US Infants

Prophylactic Antibody A Key Asset In Sanofi’s Vaccine Portfolio

Sanofi, which leads commercialization under its 2017 deal with AstraZeneca, may soon compete with a maternal RSV vaccine from Pfizer, but the US may have room for only one infant-protecting option.

Portrait of asian parent hands holding newborn baby — Beyfortus is approved for newborns and toddlers in their second RSV season • Source: Shutterstock

Sanofi received an important win in the US on 17 July when the US Food and Drug Administration approved the AstraZeneca PLC-partnered antibody Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) in infants, a key market for one of prime products in the French big pharma’s push to turn its €3bn vaccines portfolio into a €10bn ($10.9bn) business by 2030. However, a Beyfortus challenger that could still garner significant US market share is awaiting approval next month.

Pfizer Inc.’s RSV vaccine Abrysvo was approved for older adults in June shortly after the FDA approved GSK...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

11 Jun 2025

• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

Pipeline Watch: ASCO Dominates Phase III Readouts

09 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

03 Jun 2025

• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.